Business Description
Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.41 | |||||
Beneish M-Score | 13.51 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -58.6 | |||||
3-Year EBITDA Growth Rate | -60.7 | |||||
3-Year EPS without NRI Growth Rate | -66.1 | |||||
3-Year FCF Growth Rate | -49.4 | |||||
3-Year Book Growth Rate | -18.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 30.92 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.54 | |||||
9-Day RSI | 47.11 | |||||
14-Day RSI | 43.88 | |||||
6-1 Month Momentum % | 13.4 | |||||
12-1 Month Momentum % | -79.26 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.6 | |||||
Quick Ratio | 2.16 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 375.96 | |||||
Days Sales Outstanding | 287.42 | |||||
Days Payable | 481.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.9 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 52.62 | |||||
Operating Margin % | -783.09 | |||||
Net Margin % | -776.64 | |||||
ROE % | -57.38 | |||||
ROA % | -53.91 | |||||
ROIC % | -81.87 | |||||
ROC (Joel Greenblatt) % | -957.46 | |||||
ROCE % | -56.36 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.04 | |||||
PB Ratio | 0.45 | |||||
Price-to-Tangible-Book | 2.18 | |||||
EV-to-EBIT | -1.54 | |||||
EV-to-Forward-EBIT | -1.61 | |||||
EV-to-EBITDA | -1.68 | |||||
EV-to-Forward-EBITDA | -2.59 | |||||
EV-to-Revenue | 11.72 | |||||
EV-to-Forward-Revenue | 1.39 | |||||
EV-to-FCF | -1.73 | |||||
Price-to-Net-Current-Asset-Value | 3.28 | |||||
Price-to-Net-Cash | 1.64 | |||||
Earnings Yield (Greenblatt) % | -64.94 |